Published:Oct 22, 2025
Read Time:One minute read
Baichuan launched M2 Plus, a medical AI that is evidence-augmented and marketed as a “ChatGPT” for doctors. It targets safer clinical reasoning and code creation.
On October 22, 2025, Chinese AI Lab Baichuan revealed Baichuan-M2Plus – a healthcare-focused, large model, and the latest step in their medical stack. It also unveiled an upgraded companion app, and opened API access. The company positions M2Plus to be a “doctor’s ChatGPT” optimized for clinical reasoning, and providing evidence-based answers.
Baichuan claims that M2Plus uses a six-source Evidence Augmented Reasoning framework, which combines original studies, evidence reviews and clinical guidelines with practice know-how, regulatory real-world data, public health education material, and practice know-how. The model, according to internal evaluations by the company, has a significantly lower rate of hallucinations than general-purpose LLMs – about three times lower than DeepSeek Medical’s product – and “even exceeds” the popular U.S. app OpenEvidence in the company’s testing.
This release comes after Baichuan opened-sourcing Baichuan-M2 back in August. It is framed as a push towards safer clinical decision-support and patient-facing questions and answers. The API is now open and hospitals, health platforms, and developers can integrate M2Plus in triage assistants and workflows for coding/claims, medication counseling, and guideline retrieval.
